Academy of Neurology (AAN) 2023 Annual Meeting, Amneal presented new data evaluating IPX203 (carbidopa + levodopa, CD/LD) in a nine-month open-label extension (OLE) study in Parkinson’s disease (PD) patients with motor fluctuations (NCT03877510). The OLE study involved 419 participants who completed the Phase III RISE-PD (NCT03670953). This data highlights that IPX203 could offer an additional safe and tolerable extended-release formulation of CD/LD and could offer an overall better quality of life in moderate to advanced-stage PD patients. IPX203 is currently under review by the FDA for the treatment of PD, with a PDUFA date of 30 June 2023.
AAN 2023: Amneal’s IPX203 shows promise f... - Cure Parkinson's
AAN 2023: Amneal’s IPX203 shows promise for Parkinson’s disease patients
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Significance of Newly Approved IPX203 for Parkinson Disease
Earlier this month, the FDA approved Amneal Pharmaceuticals’ investigational agent IPX203, an oral...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
Have not heard of this option before: Electroconvulsive Therapy Intervention for Parkinson’s...
Patients with Parkinson’s disease (PD) report a strong craving for sweets
"Lately, studies have shown that patients with Parkinson’s disease (PD) report a strong craving...
Gastrointestinal dysfunction in Parkinson’s Disease: absence of anti-gliadin antibodies
Gastrointestinal dysfunction in Parkinson’s Disease: absence of anti-gliadin antibodies...
Mucuna pruriens in Parkinson’s
Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study
R...
Related Posts
Mucuna Pruriens in Parkinson's disease, dosages and effects, A double-blind, randomized, controlled, crossover human study (2017)
Seafood shows promise as a future Parkinson's disease medication
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease- Nicotinamide riboside supplement shows promise as a potential therapy for Parkinson’s disease - I started taking it today!
Effect of Melatonin Administration on Mitochondrial Activity and Oxidative Stress Markers in Patients with Parkinson’s Disease 2021
